Aging is a conquest of humanity, but it brings new demands to the health system
Em salas de conferência da Fiocruz, cientistas se reuniram para enfrentar uma questão que transcende a biologia: o envelhecimento é uma doença ou uma conquista da vida? A resposta molda não apenas tratamentos médicos, mas a própria dignidade com que milhões de brasileiros idosos serão vistos e cuidados. Diante de uma transição demográfica acelerada — com 70% dos idosos dependendo do SUS e um quarto da humanidade prestes a ultrapassar os 60 anos — o Brasil reconhece que o tempo da pesquisa integrada sobre envelhecimento e doenças metabólicas não é mais o futuro, mas o presente.
- A pergunta 'o envelhecimento é uma doença?' divide pesquisadores e carrega consequências diretas para políticas públicas, financiamento científico e o modo como idosos são tratados no sistema de saúde.
- O Brasil enfrenta uma pressão demográfica urgente: 70% dos idosos dependem do SUS com ao menos uma doença crônica, enquanto a infraestrutura hospitalar e previdenciária já sente o peso dessa transição.
- A rede Fio-Meta surge como resposta estratégica, tecendo especialistas em doenças raras, câncer, nanotecnologia e saúde pública para identificar conexões inesperadas entre condições como diabetes, leishmaniose e câncer.
- O desafio central não é apenas produzir conhecimento científico, mas traduzi-lo em intervenções reais dentro do SUS — um sistema público que atende a maioria, não elites com acesso a medicina privada.
- A primeira reunião anual da rede não encerrou o debate filosófico sobre o envelhecimento, mas firmou um compromisso coletivo: tratar o envelhecimento como prioridade de saúde pública sustentada e investigada em rede.
Numa sala de conferências da Fiocruz, pesquisadores se debruçaram sobre uma questão aparentemente simples, mas de peso imenso: o envelhecimento é uma doença? A resposta não é apenas semântica — ela determina como médicos tratam pacientes idosos, como governos financiam pesquisas e como o sistema público de saúde organiza seus recursos.
Dois campos se confrontaram. Um defende que o envelhecimento é processo natural, universal entre os seres vivos que sobrevivem o suficiente, e que classificá-lo como doença transformaria idosos em pacientes permanentes. O outro argumenta que o envelhecimento é biologicamente tratável, que impulsiona as doenças que mais matam os idosos e que já existem intervenções aprovadas. A bioquímica Juliana Camacho-Pereira, da UFRJ, apresentou ambas as perspectivas e sinalizou o risco da escolha: 'Não queremos classificar os idosos como doentes.'
O contexto demográfico torna o debate urgente. Em 25 anos, cerca de um quarto da população mundial terá mais de 60 anos. Na América Latina, esse índice pode chegar a 40% até 2100. No Brasil, 70% dos idosos dependem do SUS e convivem com ao menos uma doença crônica, criando pressões em cascata sobre hospitais, pensões e cuidados de longa duração. A meta da pesquisa não é apenas prolongar a vida, mas adicionar saúde aos anos que as pessoas já vivem.
A vice-presidente de pesquisa da Fiocruz, Alda Maria da Cruz, destacou o potencial das redes integradas. A Fio-Meta reúne especialistas em doenças raras, câncer, nanotecnologia e políticas públicas — uma coalizão deliberadamente ampla que busca conexões inesperadas entre condições como diabetes e leishmaniose. O coordenador da rede, Vinicius de Frias, resumiu a visão: 'O envelhecimento é uma conquista da humanidade, mas traz novas demandas ao sistema de saúde.'
As sessões da tarde avançaram da filosofia para a estratégia, discutindo como medicina de precisão, diagnósticos avançados e modelagem computacional podem enfrentar a complexidade das doenças metabólicas. O consenso que emergiu não foi uma resposta definitiva sobre a natureza do envelhecimento, mas um compromisso: a ciência precisa se organizar em rede, traduzir descobertas em prática clínica e fazê-lo dentro da realidade do SUS — porque o futuro demográfico do Brasil já chegou.
Inside a Fiocruz conference room, researchers gathered to debate a question that sounds simple but carries enormous weight: Is aging a disease?
The answer matters more than it might seem. How scientists classify aging shapes how doctors treat it, how governments fund research, and ultimately how millions of older Brazilians receive care. At the first annual meeting of the Fio-Meta network in late May, this fundamental disagreement surfaced as the organizing tension of the entire conversation.
One camp of researchers treats aging as a natural process—something that happens to all living things that survive long enough, not a pathology requiring cure. The other camp argues aging is biologically treatable, the primary driver of age-related diseases, and already subject to approved therapies. The distinction is not academic. If aging is a disease, elderly people become patients. If it is not, they remain simply older versions of themselves. Juliana Camacho-Pereira, a biochemist from the Federal University of Rio de Janeiro's Institute of Medical Biochemistry, laid out both positions during her opening lecture on metabolic energy and aging. She noted that some researchers reject the disease classification because aging occurs universally in people who live long enough—it is not abnormal, not caused by pathogens, and therefore does not fit the traditional definition of illness. Others counter that aging is treatable, causes the diseases that kill most elderly people, and already has approved interventions. "We do not want to classify elderly people as sick," Camacho-Pereira cautioned, signaling the stakes of this semantic choice.
Why does Brazil care about aging research now? Demographics. Within 25 years, roughly one quarter of the global population will be older than 60. In Latin America and the Caribbean, that figure will reach 32 to 40 percent by 2100. Brazil's situation is particularly acute: 70 percent of the country's elderly population depends on the public health system, the SUS, and most carry at least one chronic disease. This creates cascading pressures on pensions, hospital capacity, and long-term care infrastructure. The research community's goal is not simply to extend life but to add health to the years people already live—a principle the Pan-American Health Organization has emphasized.
Alda Maria da Cruz, Fiocruz's vice president for research and biological collections, highlighted the power of integrated research networks. The Fio-Meta network is young compared to Fiocruz's traditional strength in infectious disease research, but it sits at a crucial intersection. Diabetes connects to leishmaniasis. Cancer development links to infectious disease pathways. By weaving together expertise across these domains, researchers can identify unexpected connections and design interventions that address multiple conditions at once. The network includes specialists in rare diseases, cancer research, nanotechnology, clinical platforms, and public health policy—a deliberately broad coalition.
Vinicius de Frias, who coordinates the Fio-Meta network, framed aging as a human achievement that brings new challenges. "Aging is a conquest of humanity, but it brings new demands to the health system," he said. The network's work centers on metabolic, cardiovascular, and pulmonary diseases—the chronic conditions that dominate elderly care. The Translational Research Program, which convened the meeting, exists to move scientific discovery into actual public health practice. That means designing solutions specifically for the SUS, not for wealthy private systems elsewhere.
The afternoon sessions moved from philosophy to strategy. Researchers discussed how emerging technologies—precision medicine, advanced diagnostics, computational modeling—could address the complexity of aging and metabolic disease. They explored how governance structures, research infrastructure, and clinical evidence could be organized so that laboratory findings actually reach patients in public clinics. The conversation assumed that knowledge alone is not enough; it must be translated into practice, and practice requires coordination across institutions, disciplines, and levels of government.
What emerges from this first meeting is not a settled answer to whether aging is a disease, but rather a commitment to treat aging research as a public health priority worthy of sustained, networked investigation. Brazil's demographic future is already here. The question now is whether research can keep pace.
Citas Notables
We do not want to classify elderly people as sick— Juliana Camacho-Pereira, biochemist, Federal University of Rio de Janeiro
Aging is a conquest of humanity, but it brings new demands to the health system— Vinicius de Frias, coordinator of the Fio-Meta network
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter whether aging is classified as a disease or not? Isn't that just semantics?
It shapes everything downstream. If aging is a disease, you can justify treating it like one—developing therapies, allocating research funding, training specialists. But it also means elderly people become patients, which carries its own weight. If aging is not a disease, you preserve dignity but risk underinvestment in research that could improve quality of life.
And Brazil is facing this question at a particular moment, it seems.
Exactly. The country's elderly population is growing fast, and 70 percent of them depend on the public system. They're not wealthy. They can't buy private care. So whatever researchers decide about aging, it has to work for a public health system that's already stretched.
The researchers seem to be sidestepping the disease question and focusing on networks instead. Why?
Because the real work is integration. Diabetes and leishmaniasis aren't separate problems—they intersect in the same bodies, the same communities. By connecting researchers across rare diseases, cancer, nanotechnology, you find unexpected leverage points. You move faster.
Is there a risk that focusing on networks and translation dilutes the fundamental research?
It's a tension, not a contradiction. The network exists to move knowledge into practice, but that requires basic science too. You need both the molecular detail and the systems view. The Fio-Meta network seems to be betting that you can have both if you organize deliberately.
What happens if they succeed?
Then an elderly Brazilian with diabetes and hypertension gets better care because researchers across institutions solved the problem together instead of in silos. That's the whole point.